Mallinckrodt Pharmaceuticals (MNK)
Quick facts
| Ticker | MNK (NYSE) |
|---|
Marketed products
- Cyanocobalamin Co 57 · Hematology
- Cholebrine · Other
Cholebrine works by binding to a specific target, although its exact mechanism of action is currently unknown. - IV Acetaminophen · Pain Management
Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever. - IV Acetaminophen (Treatment A) · Pain Management
Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever. - Oxycodone hydrochloride tablet 15 mg
- Repository Corticotropin Injection
- Phosphotope · Hematology
- Restoril · Neuroscience
- Xe 133 · Respiratory
Phase 3 pipeline
- COV155 · Neurology / Psychiatry
COV155 is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system. - COV795 · Immunology
COV795 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. - Fibrocaps · Other
- Gelatin sponge · Surgery/Hemostasis
Gelatin sponge is a hemostatic agent that absorbs blood and promotes clotting through physical absorption and platelet aggregation. - IK-3001 · Hematology
IK-3001 is an intravenous iron replacement therapy that replenishes depleted iron stores in patients with iron deficiency. - IV Control · Critical Care
IV Control is used to control the rate of intravenous medication administration. - Nitric Oxide plus Oxygen · Cardiovascular / Pulmonary
Nitric oxide gas combined with oxygen improves oxygenation and vasodilation in the lungs to reduce pulmonary hypertension and improve gas exchange. - PENNSAID Gel · Rheumatology / Pain Management
PENNSAID is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation at the site of application.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: